These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 1803625

  • 1. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR, Ferguson JM, McLaughlin LF, Burnouf T, Prowse CV.
    Thromb Haemost; 1991 Nov 01; 66(5):609-13. PubMed ID: 1803625
    [Abstract] [Full Text] [Related]

  • 2. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF, Drummond O, MacGregor IR.
    Thromb Haemost; 1992 Nov 10; 68(5):511-5. PubMed ID: 1455396
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB.
    Haemophilia; 2005 Nov 10; 11(6):583-8. PubMed ID: 16236107
    [Abstract] [Full Text] [Related]

  • 4. Thrombogenicity of a factor IX concentrate quantitated in a canine model.
    MacGregor IR, Ferguson JF, Dawes J, McLaughlin L, Prowse CV.
    Blood Coagul Fibrinolysis; 1990 Nov 10; 1(1):23-30. PubMed ID: 2102787
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV, Williams AE.
    Thromb Haemost; 1980 Oct 31; 44(2):81-6. PubMed ID: 6779401
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs.
    Littlewood JD, Dawes J, Smith JK, Feldman PA, Haddon ME, McQuillan TA, Foster PR, Ferguson J, Prowse CV.
    Br J Haematol; 1987 Apr 31; 65(4):463-8. PubMed ID: 3580303
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I.
    Thromb Haemost; 2007 Oct 31; 98(4):790-7. PubMed ID: 17938803
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD.
    Br J Haematol; 1991 Dec 31; 79(4):606-11. PubMed ID: 1772782
    [Abstract] [Full Text] [Related]

  • 13. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model.
    Harrison J, Abildgaard C, Lazerson J, Culbertson R, Anderson G.
    Thromb Res; 1985 Apr 15; 38(2):173-88. PubMed ID: 4002204
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, Buss DH, Prough DS, Cordell AR.
    J Thorac Cardiovasc Surg; 1990 Mar 15; 99(3):518-27. PubMed ID: 2308370
    [Abstract] [Full Text] [Related]

  • 16. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM.
    J Lab Clin Med; 1993 Mar 15; 121(3):394-405. PubMed ID: 8445288
    [Abstract] [Full Text] [Related]

  • 17. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP, Klessen C, Jablonowski C, Meerbach W, Dornheim G.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984 Mar 15; 111(5):645-61. PubMed ID: 6083940
    [Abstract] [Full Text] [Related]

  • 18. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ, Patiwael S, Tripathi S, Meijers JC.
    Thromb Res; 2016 Mar 15; 139():102-10. PubMed ID: 26916304
    [Abstract] [Full Text] [Related]

  • 19. [Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings)].
    Hofmann V, Ermanni M, Straub PW.
    Schweiz Med Wochenschr; 1978 Oct 14; 108(41):1600. PubMed ID: 694497
    [Abstract] [Full Text] [Related]

  • 20. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP, Hampton KK, Dasani H, Lee CA, Giangrande PL, Harman C, Lee ML, Preston FE.
    Br J Haematol; 1994 Aug 14; 87(4):782-8. PubMed ID: 7986719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.